You will first need to register if it's your first visit.
Roche is committed to pioneering progress in precision medicine
Roche continuously develops new targeted treatment options based on agnostic biomarkers
Biomarkers likely to have approved targeted therapies with tumour agnostic indicators by 2025*
*Multiple secondary sources used to cross validate information, including Trialtrove, clinicatrials.gov, EudraCT, ChiCTR; FDA approval timeline estimation based on Ph3 PCD + 8 months review; analysis based on current Phase 1/2, Phase 2 and Phase 3 trials with inclusion criteria requiring patient selection based on alterations to specific biomarkers; assumption made that all ongoing trials will lead to approval; “biomarker“ defined as any biological molecule found in blood or tissues that has either pronostic or predictive significance in cancer treatment, and for which the effectiveness of a therapy in a patient population defined by the detection of this molecule or molecular aberration is currently being tested or has already been approved.
CGP: comprehensive genomic profiling; FDA: U.S. Food and Drug Administration; HRD: homologous recombination deficiency;IHC: immunohistochemistry; MMR: mismatch repair; MSI-H: microsatellite instability-high; Ph: Phase; TMB: tumour mutational burden.